FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W832136688> ?p ?o ?g. }

• W832136688 endingPage "5022" @default.
• W832136688 startingPage "5022" @default.
• W832136688 abstract "Abstract Background Lymphotropism of HCV induces chronic immune stimulation, facilitating production of wide variety of autoantibodies, leading to HCV driven autoimmunity. Immune thrombocytopenic purpura (ITP) is one of extra hepatic manifestations of autoimmune diseases in HCV infection. The treatment landscape of hepatitis C virus infection has been dramatically altered in 2013 with the approvals of the second-generation protease inhibitor simeprevir and the nucleotide polymerase inhibitor sofosbuvir. In most patients treated with the direct-acting antiviral agent (DAA), HCV RNA became undetectable. However a little is known about how DAA therapy affects autoimmune diseases associated with HCV, especially in ITP. Cessation of immune stimulation by HCV following the treatment may alter immune responses and may modify autoimmune diseases. We report here a case of acute exacerbation of ITP following DAA treatment. DAA therapy appears to precipitate acute exacerbation of thrombocytopenia and ITP became refractory to all treatments including the measures that used to induce remission prior to DAA treatment. Case report A 67-year-old man was diagnosed chronic HCV infection, genotype 1b, in 1997. He failed treatment with Interferons. Chronic active hepatitis subsequently progressed into cirrhosis with portal hypertension. His ITP required frequent treatments with Prednisone and IVIG. It became severe in early 2013. His platelet counts were low at 10,000. He responded well to high dose Prednisone but could not continue because of worsening diabetes. He also failed Rituxan. He received multiple treatments including eltrombopag and romiplostin which he did not respond well to. His ITP finally stabilized with monthly infusion of WinRho as maintenance therapy with platelet counts hovering around 40.000 for 6 months. In March 2014, he was started on HCV treatment with simeprevir, sofosbuvir and ribavirin. His baseline platelet count prior to the new treatment was in the 50000’s. It plummeted to below 10.000 two weeks into treatment. He developed multiple ecchymosis and blood blisters in the mouth. He completed his HCV treatment on June 3, 2014. His viral load was no longer detectable. However, ITP remained refractory and severe with platelet counts around 10,000. High dose Prednisone or WinRho which had been effective in raising platelet counts previously were no longer effective after DAA therapy. During this acute exacerbation of ITP, he was treated with IVIG 3 times a week and low dose Prednisone and NPlate weekly with increasing dosage. He developed frequent blood blisters in mouth and gum bleeding requiring emergency room visits and hospitalization where he received platelet transfusions along with IVIGG and high dose Prednisone. His hemoglobin was stable throughout. IVIGG was reduced to 2 times a week. At 8 weeks following completion of DAAs, his platelet count improved to 40.000s range without clinical sign of bleeding. Discussion It has been shown that the frequency of B-cell production of anti- GPIIb-IIIa antibody, an antibody against the major platelet surface autoantigen (BP IIb-IIIa) recognized by anti-platelet antibodies in patients with idiopathic thrombocytopenic purpura (ITP), was greater in HCV-ITP (9). An inverse correlation was found between platelet count and B-cell anti–GPIIb-IIIa Ab production in 51 patients with liver cirrhosis (73% with hepatitis C). In our patient, ITP was stable with maintenance infusion of WinRho for 6 months. Acute exacerbation of ITP 2 weeks into DAA therapy suggests that it was triggered by the DAAs. Thrombocytopenia is a well-recognized complication of interferon therapy for treatment of viral hepatitis. Simeprevir and sofosbuvir however, are not well known to affect the platelet count. A little is known on effect of DAAs on thrombocytopenia. Immune alteration following eradication of HCV and subsequent modification of autoimmunity could affect course of ITP associated with HCV infection. Meanwhile, it is important for physicians and patients to be aware of potentially dangerous complications of these second generation DAAs. Disclosures No relevant conflicts of interest to declare." @default.
• W832136688 created "2016-06-24" @default.
• W832136688 creator A5011580590 @default.
• W832136688 creator A5024578473 @default.
• W832136688 creator A5039927477 @default.
• W832136688 creator A5042501771 @default.
• W832136688 creator A5051842349 @default.
• W832136688 date "2014-12-06" @default.
• W832136688 modified "2023-09-28" @default.
• W832136688 title "Second Generation Direct-Acting Antiviral Agents Eradicate Hepatitis C Virus (HCV) but Exacerbate Thrombocytopenia in a Patient with HCV-Associated Immune Thrombocytopenic Purpura (ITP): Case Report" @default.
• W832136688 doi "https://doi.org/10.1182/blood.v124.21.5022.5022" @default.
• W832136688 hasPublicationYear "2014" @default.
• W832136688 type Work @default.
• W832136688 sameAs 832136688 @default.
• W832136688 citedByCount "3" @default.
• W832136688 countsByYear W8321366882015 @default.
• W832136688 countsByYear W8321366882019 @default.
• W832136688 countsByYear W8321366882021 @default.
• W832136688 crossrefType "journal-article" @default.
• W832136688 hasAuthorship W832136688A5011580590 @default.
• W832136688 hasAuthorship W832136688A5024578473 @default.
• W832136688 hasAuthorship W832136688A5039927477 @default.
• W832136688 hasAuthorship W832136688A5042501771 @default.
• W832136688 hasAuthorship W832136688A5051842349 @default.
• W832136688 hasConcept C126322002 @default.
• W832136688 hasConcept C159654299 @default.
• W832136688 hasConcept C203014093 @default.
• W832136688 hasConcept C2522874641 @default.
• W832136688 hasConcept C2776029263 @default.
• W832136688 hasConcept C2776408679 @default.
• W832136688 hasConcept C2776455275 @default.
• W832136688 hasConcept C2777014857 @default.
• W832136688 hasConcept C2777203481 @default.
• W832136688 hasConcept C2778390639 @default.
• W832136688 hasConcept C2778720950 @default.
• W832136688 hasConcept C2778986448 @default.
• W832136688 hasConcept C2779771385 @default.
• W832136688 hasConcept C2780040827 @default.
• W832136688 hasConcept C2780588981 @default.
• W832136688 hasConcept C2993327898 @default.
• W832136688 hasConcept C71924100 @default.
• W832136688 hasConcept C8891405 @default.
• W832136688 hasConceptScore W832136688C126322002 @default.
• W832136688 hasConceptScore W832136688C159654299 @default.
• W832136688 hasConceptScore W832136688C203014093 @default.
• W832136688 hasConceptScore W832136688C2522874641 @default.
• W832136688 hasConceptScore W832136688C2776029263 @default.
• W832136688 hasConceptScore W832136688C2776408679 @default.
• W832136688 hasConceptScore W832136688C2776455275 @default.
• W832136688 hasConceptScore W832136688C2777014857 @default.
• W832136688 hasConceptScore W832136688C2777203481 @default.
• W832136688 hasConceptScore W832136688C2778390639 @default.
• W832136688 hasConceptScore W832136688C2778720950 @default.
• W832136688 hasConceptScore W832136688C2778986448 @default.
• W832136688 hasConceptScore W832136688C2779771385 @default.
• W832136688 hasConceptScore W832136688C2780040827 @default.
• W832136688 hasConceptScore W832136688C2780588981 @default.
• W832136688 hasConceptScore W832136688C2993327898 @default.
• W832136688 hasConceptScore W832136688C71924100 @default.
• W832136688 hasConceptScore W832136688C8891405 @default.
• W832136688 hasIssue "21" @default.
• W832136688 hasLocation W8321366881 @default.
• W832136688 hasOpenAccess W832136688 @default.
• W832136688 hasPrimaryLocation W8321366881 @default.
• W832136688 hasRelatedWork W2019722329 @default.
• W832136688 hasRelatedWork W2096422666 @default.
• W832136688 hasRelatedWork W2097888434 @default.
• W832136688 hasRelatedWork W2114705120 @default.
• W832136688 hasRelatedWork W2176407467 @default.
• W832136688 hasRelatedWork W2408290568 @default.
• W832136688 hasRelatedWork W2417556805 @default.
• W832136688 hasRelatedWork W2558322432 @default.
• W832136688 hasRelatedWork W2893352027 @default.
• W832136688 hasRelatedWork W832136688 @default.
• W832136688 hasVolume "124" @default.
• W832136688 isParatext "false" @default.
• W832136688 isRetracted "false" @default.
• W832136688 magId "832136688" @default.
• W832136688 workType "article" @default.